Time to thrombolysis and factors contributing to delays in patients presenting with ST-elevation myocardial infarction at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
DOI:
https://doi.org/10.7196/SAMJ.2023.v113i9.500Keywords:
thrombolysis, acute coronary syndrome, STEMIAbstract
Background. Acute coronary syndrome is a public health burden both worldwide and in South Africa (SA). Guidelines recommend thrombolysis within 1 hour of symptom onset and 30 minutes of hospital arrival for patients with ST-elevation myocardial infarction (STEMI) in order to prevent morbidity and mortality. There is a paucity of data pertaining to the time between onset of chest pain and thrombolysis in STEMI patients in SA.
Objectives. To elucidate the time to thrombolytic therapy, establish the reasons for treatment delays, and calculate the loss of benefit of thrombolysis associated with delays in treatment of patients presenting with STEMI at Chris Hani Baragwanath Academic Hospital (CHBAH), Johannesburg, SA.
Method. A prospective observational study of 100 consecutive patients with STEMI was conducted at CHBAH (2021 - 2022).
Results. The mean (standard deviation) age was 55.6 (11.6) years, with a male predominance (78%). Thrombolytic therapy was administered to 51 patients, with a median (interquartile range (IQR)) time to thrombolysis of 360 (258 - 768) minutes; 10 of the patients who received a thrombolytic (19.6%) did so within 30 minutes of arrival at the hospital. The median (IQR) time from symptom onset to calling for help was 60 (30 - 240) minutes, the median time from arrival of help to hospital arrival was 114 (48 - 468) minutes, and the median in-hospital delay to thrombolysis after arrival was 105 (45 - 240) minutes. Numerous reasons that led to delay in treatment were identified, but the most frequent was prehospital delays related to patient factors. Late presentation resulted in 26/49 patients (53.1%) not receiving thrombolytic therapy. Five patients died and 43 suffered from heart failure. Thirty per 1 000 participants could have been saved had they received thrombolytic therapy within 1 hour from the onset of chest pain.
Conclusion. Prehospital and hospital-related factors played a significant role in delays to thrombolysis that led to increased morbidity and mortality of patients with STEMI.
References
Tibazarwa K, Ntyintyane L, Sliwa K, et al. A time bomb of cardiovascular risk factors in South Africa:
Results from the Heart of Soweto Study ‘Heart Awareness Days’. Int J Cardiol 2009;132(2):233-239.
https://doi.org/10.1016/j.ijcard.2007.11.067
Mbewu A. The burden of cardiovascular disease in sub-Saharan Africa. SA Heart 2009;6(1):4-10.
https://doi.org/10.24170/6-1-2005
Statistics South Africa. Mortality and causes of death in South Africa: Findings from death notification:
Statistical release P0309.3. Pretoria: Stats SA, 15 June 2021. https://www.statssa.gov.za/
publications/P03093/P030932018.pdf (accessed 20 September 2022).
Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial
infarction in patients presenting with ST-segment elevation: The Task Force for the management of
acute myocardial infarction in patients presenting with ST-segment elevation of the European Society
of Cardiology (ESC). Eur Heart J 2018;39(2):119-177. https://doi.org/10.1093/eurheartj/ehx393
Claeys MJ, Sinnaeve PR, Convens C, et al. STEMI mortality in community hospitals versus PCIcapable
hospitals: Results from a nationwide STEMI network programme. Eur Heart J 2012;1(1):40-47.
https://doi.org/10.1177/2048872612441579
Kaifoszova Z, Kala P, Alexander T, et al. Stent for Life Initiative: Leading example in building STEMI
systems of care in emerging countries. EuroIntervention 2014;10(Suppl T): T87-T95. https://doi.
org/10.4244/eijv10sta14
Snyders A, Delport R. Referral pathways for reperfusion of STEMI – developing strategies for
appropriate intervention: The SA Heart STEMI early intervention project. SA Heart 2015;12(2):74-80.
https://doi.org/10.24170/12-2-1722
Maharaj RC, Geduld H, Wallis LA. Door-to-needle time for administration of fibrinolytics in acute
myocardial infarction in Cape Town. S Afr Med J 2012;102(4):241-244.
Meel R, Gonçalves R. Time to fibrinolytics for acute myocardial infarction: Reasons for delays at
Steve Biko Academic Hospital, Pretoria, South Africa. S Afr Med J 2015;106(1):92-96. https://doi.
org/10.7196/SAMJ.2016.v106i1.9801
Stassen W, Wallis L, Lambert C, Castren M, Kurland L. Percutaneous coronary intervention still not
accessible for many South Africans. Afr J Emerg Med 2017;7(3):105-107. https://doi.org/10.1016/j.
afjem.2017.04.009
Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial
infarction: Reappraisal of the golden hour. Lancet 1996;348(9030):771-775. https://doi.org/10.1016/
s0140-6736(96)02514-7
O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of STelevation
myocardial infarction: A report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61(4):e78-e140. https://
doi.org/10.1016/j.jacc.2012.11.019
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018).
Circulation2018;138(20):e618-e651. https://doi.org/10.1161/cir.0000000000000617
White HD, van de Werf FJJ. Thrombolysis for acute myocardial infarction. Circulation
;97(16):1632-1646. https://doi.org/10.1161/01.cir.97.16.163
Rovelli F, de Vita C, Feruglio GA, et al. GISSI trial: Early results and late follow-up. J Am Coll Cardiol
;10(5):33B-39B. https://doi.org/10.1016/s0735-1097(87)80426-6
Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J
;34(3):318-327.
Lim SC, Rahman A, Yaacob NM. Pre-hospital factors influencing time of arrival at emergency
departments for patients with acute ST-elevation myocardial infarction. Malays J Med Sci
;26(1):87-98. https://doi.org/10.21315/mjms2019.26.1.8
Yao H, Ekou A, Niamkey T, et al. Acute coronary syndromes in sub‐Saharan Africa: A 10‐year
systematic review. J Am Heart Assoc 2022;11(1):e021107. https://doi.org/10.1161/jaha.120.021107
Rawles JM. Quantification of the benefit of earlier thrombolytic therapy: Five-year results of the
Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1997;30(5):1181-1186. https://
doi.org/10.1016/s0735-1097(97)00299-4
Castle N, Naidoo R, Owen R. Initiation of pre-hospital thrombolysis in South Africa. S Afr Med J
;96(1):28-31.
Lynch A, Sobuwa S, Castle N. Barriers to the implementation of prehospital thrombolysis in the
treatment of ST-segment elevation myocardial infarction in South Africa: An exploratory inquiry. Afr
J Emerg Med 2020;10(4):243-248. https://doi.org/10.1016/j.afjem.2020.08.001
National Department of Health, South Africa: Essential Drugs Programme. Standard Treatment
Guidelines and Essential Medicines List. 5th ed. Pretoria: NDoH, 2019: Chapter 3.2. https://
knowledgehub.health.gov.za/system/files/elibdownloads/2023-04/Hospital%2520Level%2520%2528A
dult%2529%25202019_v2.0.pdf (accessed 20 September 2022).
National Department of Health, South Africa: Essential Drugs Programme. Primary Healthcare
Standard Treatment Guidelines and Essential Medicine List. 7th ed. Pretoria: NDoH, 2020: Chapter
4. https://knowledgehub.health.gov.za/system/files/elibdownloads/2023-04/Primary%2520Healthc
are%2520STGs%2520and%2520EML%25207th%2520edition%2520-%25202020-v2.0.pdf (accessed
September 2022).
National Department of Health, South Africa. Recommendation for alternative therapy for
streptokinase. EDP022019/01. https://www.samedical.org/file/973 (accessed 20 September 2022).
Kramer E. ‘No one may be refused emergency medical treatment’ – ethical dilemmas in South African
emergency medicine. S Afr J Bioethics Law 2008;1(2):53-56. https://hdl.handle.net/10520/EJC64473
(accessed 19 April 2023).
Kakou-Guikahue M, N’Guetta R, Anzouan-Kacou J-B, et al. Optimizing the management of acute
coronary syndromes in sub-Saharan Africa: A statement from the AFRICARDIO 2015 Consensus
Team. Arch Cardiovasc Dis 2016;109(6-7):376-383. https://doi.org/10.1016/j.acvd.2015.12.005
Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. J Am Coll Cardiol
;6(3):179-186. https://doi.org/10.1016/j.jchf.2017.09.015
Alkhalil M, Kearney A, MacElhatton D, Fergie R, Dixon L. The prognostic role of mid-range ejection
fraction in ST-segment elevation myocardial infarction. Int J Cardiol 2020;321:12-17. https://doi.
org/10.1016/j.ijcard.2020.07.001
Perelshtein Brezinov O, Klempfner R, Zekry SB, Goldenberg I, Kuperstein R. Prognostic value of
ejection fraction in patients admitted with acute coronary syndrome. Medicine 2017;96(9):e6226.
https://doi.org/10.1097/md.0000000000006226
Kraus S, Ogunbanjo G, Sliwa K, Ntusi NAB. Heart failure in sub-Saharan Africa: A clinical approach. S
Afr Med J 2015;106(1):23-31. https://doi.org/10.7196/SAMJ.2016.v106i1.10325
Leon S, Meel R. Impact of the COVID-19 pandemic on acute coronary syndrome patients admitted
to an urban academic hospital in Soweto, South Africa. Abstracts: SA Heart Congress 2021. SA Heart
;18(3):176. https://journals.co.za/doi/pdf/10.10520/ejc-saheart-v18-n3-a4 (accessed 20 August
.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 I tickley, S A van Blydenstein, R Meel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
